drugset / Trial / NCT01355497

Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer (NSCLC) on First Line Platinum

NCT01355497

Phase 3 Completed 330 enrolled GTx
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to determine if the investigational drug GTx-024 can help patients with non small cell lung cancer increase physical function and maintain or gain muscle.

Timeline

Start
2011-07
Primary completion
2013-05
Completion
2014-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Enobosarm Small molecule 3 mg Oral